Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.

Literature DB >> 14990742

Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.

Anjeanette Roberts¹, Jon D Reuter, Jean H Wilson, Stuart Baldwin, John K Rose.

Abstract

We generated an attenuated, recombinant vesicular stomatitis virus (VSV) expressing high levels of the cottontail rabbit papillomavirus (CRPV) L1 protein from an upstream site in the VSV genome. Rabbits vaccinated once with this VSV-L1 recombinant produced high levels of anti-L1 antibody and were completely protected against papilloma formation after challenge with CRPV. In contrast, animals vaccinated only once with a VSV vector expressing lower levels of L1 from a downstream site in the VSV genome generated lower levels of L1 antibody and demonstrated only incomplete protection from papilloma formation after challenge. We conclude that the level of L1 protein expression is critical in generating complete immunity with a single-dose vaccine.

Entities: Disease Species

Mesh：

Substances：

Year: 2004 PMID： 14990742 PMCID： PMC353748 DOI： 10.1128/jvi.78.6.3196-3199.2004

Source DB: PubMed Journal: J Virol ISSN： 0022-538X Impact factor: 5.103

19 in total

1. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies.

Authors: B Schlereth; J K Rose; L Buonocore; V ter Meulen; S Niewiesk
Journal: J Virol Date: 2000-05 Impact factor: 5.103

2. Codon usage-mediated inhibition of HIV-1 gag expression in mammalian cells occurs independently of translation.

Authors: Alexander Kofman; Marcus Graf; Ludwid Deml; Hans Wolf; Ralf Wagner
Journal: Tsitologiia Date: 2003

3. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.

Authors: Karl Haglund; Ingrid Leiner; Kristen Kerksiek; Linda Buonocore; Eric Pamer; John K Rose
Journal: J Virol Date: 2002-03 Impact factor: 5.103

4. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.

Authors: N F Rose; A Roberts; L Buonocore; J K Rose
Journal: J Virol Date: 2000-12 Impact factor: 5.103

5. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease.

Authors: Jon D Reuter; Beatriz E Vivas-Gonzalez; Daniel Gomez; Jean H Wilson; Janet L Brandsma; Heather L Greenstone; John K Rose; Anjeanette Roberts
Journal: J Virol Date: 2002-09 Impact factor: 5.103

6. Recombinant vesicular stomatitis viruses from DNA.

Authors: N D Lawson; E A Stillman; M A Whitt; J K Rose
Journal: Proc Natl Acad Sci U S A Date: 1995-05-09 Impact factor: 11.205

7. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription.

Authors: L E Iverson; J K Rose
Journal: Cell Date: 1981-02 Impact factor: 41.582

8. Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.

Authors: Kazu Okuma; Kevin P Dalton; Linda Buonocore; Elizabeth Ramsburg; John K Rose
Journal: J Virol Date: 2003-08 Impact factor: 5.103

9. A controlled trial of a human papillomavirus type 16 vaccine.

Authors: Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Eliav Barr; Frances B Alvarez; Lisa M Chiacchierini; Kathrin U Jansen
Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245

10. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors: F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal: J Virol Date: 1995-06 Impact factor: 5.103

34 in total

1. A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region.

Authors: Takuji Daito; Kan Fujino; Tomoyuki Honda; Yusuke Matsumoto; Yohei Watanabe; Keizo Tomonaga
Journal: J Virol Date: 2011-09-21 Impact factor: 5.103

Review 2. Nonsegmented negative-strand viruses as vaccine vectors.

Authors: Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal: J Virol Date: 2006-11 Impact factor: 5.103

3. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors: Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal: J Virol Date: 2017-03-29 Impact factor: 5.103

4. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals.

Authors: Elizabeth Ramsburg; Jean Publicover; Linda Buonocore; Amanda Poholek; Michael Robek; Amy Palin; John K Rose
Journal: J Virol Date: 2005-12 Impact factor: 5.103

10. Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.

Authors: Jason R Smedberg; Marlena M Westcott; Maryam Ahmed; Douglas S Lyles
Journal: J Virol Date: 2013-11-06 Impact factor: 5.103